Press Releases – Coave Therapeutics

Press Releases

30 May 2023

Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

4 May 2023

Coave Therapeutics Demonstrates its Modified coAAV Vectors Outperform AAV9 to Address Neurological Disorders

16 March 2023

Coave Therapeutics to Present at Upcoming Conferences

20 September 2022

Coave Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

12 September 2022

Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders

6 September 2022

Coave Therapeutics Strengthens Leadership Team with the Appointments of Catherine Mathis as Vice President Regulatory Affairs and Julien Berger as Head of Legal Affairs

29 June 2022

Coave Therapeutics Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Next-generation Gene Therapies Targeting CNS Diseases

9 June 2022

Coave Therapeutics and ABL enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for process development of AAV-based gene therapy

3 May 2022

Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT

27 April 2022

Coave Therapeutics will be presenting an abstract at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held in Denver, Colorado 1-4 May 2022. The meeting will also be available for virtual attendees 11-12 May.